Drug Trial Radar · NCT04722653
A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
Last checked: Nov 19, 2026Latest source record: Apr 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Feb 2, 2021
Primary completion
Apr 27, 2021
Study completion Apr 27, 2021
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 20 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study looks at how a new medicine called NNC0194-0499 works in the body of Japanese men and non-Asian men. Japanese participants will either get NNC0194-0499 or placebo - which treatment participants get is decided by chance. Non-Asian participants will get NNC0194-0499. Participants will get 1 or 2 injections of the study medicine. It will be injected with a needle into a skin fold on the stomach. The study will last for a maximum of 66 days. Participants will have 8 scheduled visits with the study doctor. For 1 of the visits participants will stay at the clinic for 6 days (5 nights). The study includes blood sampling. Participants will not be able to take part in the study if the study doctor thinks there is a risk for participants health.
Conditions
- Non-alcoholic Steatohepatitis
Interventions
NNC0194-0499Drug
1 single dose administered subcutaneously (s.c. - under the skin)
Placebo (NNC0194-0499 )Drug
1 single dose administered subcutaneously (s.c. - under the skin).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of treatment emergent adverse events (TEAEs)Time frame: From Day 1 (pre-dose) until completion of the post-treatment period at follow-up (Day 36)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.